Biome Releases First Half FY2024 Results
● Biome reports record half year and quarterly sales revenue (H1FY24 $6.02m;
Q2FY24 $3.3m)
● FY24 revenue guidance upgraded to $12.5m in January 2024
● Biome signed landmark biological intellectual property agreement to
develop and solely own multiple novel probiotic strains in December 2023
● Biome announced new cholesterol-lowering probiotic, Biome Cholesterol™
Probiotic for release in H2FY24
● Biome successfully launched three new condition-specific live
biotherapeutic products, Biome Dental™ Probiotic, Biome Lax™ Probiotic
and Biome Recovery™ Probiotic in H1FY24
● Biome management reaffirms the company expects to achieve first positive
monthly EBITDA by June 2024
● January’s launch into the European health retail channel has commenced
with key distributor partners including CLF in the United Kingdom and
iiHealthfoods in the Republic of Ireland
● Biome reports gross margin increase to 60% as at 31 December 2023
Ann: Biome Releases First Half FY2024 Results, page-2
Add BIO (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
65.0¢ |
Change
-0.020(2.99%) |
Mkt cap ! $142.4M | |||
| Open | High | Low | Value | Volume |
| 68.0¢ | 68.0¢ | 64.0¢ | $118.4K | 180.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 81106 | 65.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 65.5¢ | 2801 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| BIO (ASX) Chart |